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Abstract
In developed countries, colorectal cancer (CRC) is the third most common malignancy, but it is the second most
frequent cause of cancer-related death. Clinicians are still faced with numerous challenges in the treatment of this
disease, and future approaches which target the molecular features of the disorder will be critical for success in this
disease setting. Genetic analyses of many solid tumours have shown that up to 100 protein-encoding genes are
mutated. Within CRC, numerous genetic alterations have been identified in a number of pathways. Therefore,
understanding the molecular pathology of CRC may present information on potential routes for treatment and may
also provide valuable prognostic information. This will be particularly pertinent for molecularly targeted treatments,
such as anti-vascular endothelial growth factor therapies and anti-epidermal growth factor receptor (EGFR)
monoclonal antibody therapy. KRAS and BRAF mutations have been shown to predict response to anti-EGFR
therapy. As EGFR can also signal via the phosphatidylinositol 3-kinase (PI3K) kinase pathway, there is considerable
interest in the potential roles of members of this pathway (such as PI3K and PTEN) in predicting treatment
response. Therefore, a combined approach of new techniques that allow identification of these biomarkers
alongside interdisciplinary approaches to the treatment of advanced CRC will aid in the treatment decision-making
process and may also serve to guide future therapeutic approaches.
Keywords: Clinical decision-making process, Molecularly targeted treatment, Therapy response, Prediction, Therapy
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Introduction to colorectal cancer
Colorectal cancer (CRC) is the fourth leading cause of
cancer-related mortality worldwide, accounting for over
600,000 deaths annually [1]. Estimates for CRC in the 40
European countries studied in 2008 [1] indicated that
CRC was the most common cancer (436,000 cases, 13.6%
of total) and the second most common cause of death
from cancer (212,000 deaths, 12.3% of total). Recent
genome-wide analyses of solid tumours, including CRC,
have shown mutations in between 20 and 100 protein-
encoding genes [2-7]. A number of key genetic and epi-
genetic alterations which lead to malignant transformation
have been identified in CRC, and these include aberrations
in genes involved in the chromosomal instability (CIS)
pathway, the microsatellite instability (MSI) pathway, the
hMYH pathway and the CpG island methylation pathway
[8]. Recent data have shown that KRAS and BRAF muta-
tions predict response to anti-epidermal growth factor re-
ceptor (EGFR) therapy reviewed in [9]. Great strides have
been made in the early detection and diagnosis of CRC,
including population-based screening, which has the po-
tential to prevent up to 60% of CRC deaths reviewed in
[10]. Despite this, however, up to 56% of newly diagnosed
CRC patients present with either nodal or distant metasta-
ses [11]. Prognosis is poor for these patients, with an
overall 5-year survival rate of 6.6%–11.9% for Dukes D
patients [11,12]. Therefore, further developments are es-
sential in order to increase the 5-year survival rate and to
improve the overall quality of life (QoL) for patients with
this disease.
The role of predictive, preventive and personalised
medicine in CRC
Predictive, preventive and personalised medicine (PPPM)
endeavours to promote a paradigm shift in our current
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healthcare approach. The PPPM approach aims to pre-
dict individual predisposition before onset of the disease,
to provide targeted preventive measures and to create per-
sonalised treatment algorithms tailored to the individual.
The concept aims to move from delayed intervention to
predictive medicine tailored to the person, from reactive
to preventive medicine and from disease to wellness. It is
hoped that this will provide a more cost-effective manage-
ment of major diseases, such as cancer, in the future. The
critical role of PPPM in the modernisation of healthcare
systems has been acknowledged as a priority by global and
regional organisations and health-related institutions, such
as the Organisation of United Nations, the European
Union and The National Institutes of Health. In CRC, the
potential value of biomarkers for PPPM is strong, and
there have been recent increased efforts to incorporate the
use of such markers into healthcare systems. Biomarkers
could be used to:
 Identify disease predisposition
 Identify early disease and aid appropriate timely
treatment intervention
 Aid molecular classification of the disease, with a
view to provide better disease understanding and
more effective, targeted treatment options
 Identify patient populations that are more likely to
derive clinical benefit from current and future
treatment options.
Whilst the identification of biomarkers of predispos-
ition and of early stage disease is critical, the focus of
this review article will be on the use of markers as an
aid to the classification of CRC and their role as poten-
tial companion diagnostics.
Classification of CRC
Classification of CRC has traditionally been based on histo-
pathological features. Molecular studies have allowed a sig-
nificant appreciation of the heterogeneous nature of CRC.
However, it has long been known, based on morphological
criteria, that CRC is not a homogenous disease. For ex-
ample, even before the advent of molecular classification of
tumours, it was noted that the rare, but histologically
distinct ‘medullary carcinoma’ occurs almost exclusively on
the right side of the colon and is associated with an
improved prognosis compared to the standard histological
types [13].
More recently, the molecular changes underlying these
phenotypical appearances have been elucidated. To use
the example above, it has now been shown that medul-
lary carcinoma of the colon shows MSI with loss of the
DNA mismatch repair (MMR) enzymes, such as MLH-1,
MSH-2, MSH-6 and PMS-2 [13]. It is also now known
that this molecular signature is shared by the more
common serrated tumour pathway. This loss of DNA mis-
match repair activity may be caused by mutation of one of
these genes, as seen in hereditary non-polyposis colorectal
cancer (HNPCC). More commonly, these tumours arise
sporadically, and the loss of MMR function is due to epi-
genetic silencing of one of the genes, as a result of pro-
moter methylation. High-level MSI (MSI-H) comprises
15% of sporadic CRC, and these are positively correlated
with patients being female, over 60 years of age, having
BRAF mutations and being right-sided tumours [14]. It is
interesting to note that although there is a continuous
increase in the rate of MSI-H tumours as one progresses
proximally from the rectum to the ascending colon, the
previously popular view of dichotomous (proximal and
distal) tumours has been challenged by recent data [15].
In addition to the finding that CpG island methylator
phenotype (CIMP)-high tumours have particular pheno-
typical and prognostic features, they also evolve from a
different precursor lesion than those tumours which are
microsatellite stable (MSS) and show CIS. CIMP-high
tumours form part of the serrated pathway and develop
from precursor lesions, which have a different histological
appearance to standard colonic adenomas [16,17]. In
addition to the known difference in prognosis for these
tumours, there has also been the suggestion that they may
also be associated with a lack of clinical benefit from stand-
ard 5-fluorouracil (5-FU)-based chemotherapy [18,19].
This molecular sub-typing of CRC has advanced to the
stage where we can now begin to consider a molecular
classification-based approach for CRC. Jass suggested
one such classification and proposed five molecular sub-
classifications (see Figure 1), based on levels of MSI and
CIMP [17].
Introduction to current therapies
Four key approaches are currently used for the treat-
ment of CRC: surgery, chemotherapy, radiotherapy and
targeted therapies. The mainstay of CRC treatment is
surgery. In early stage disease (stage 0 or I), surgical ex-
cision can be used without need for further treatment
options, as the recurrence rate for node-negative T1
colorectal cancer is very low [21]. Many studies have
now shown that adjuvant therapy has a survival benefit
for patients with stage III disease, and therefore, this is
the standard of care. The situation is not yet clear for
patients with stage II CRC, however, in which there is
somewhat conflicting evidence regarding the benefit of ad-
juvant therapy. It is agreed that ‘high-risk’ stage II patients
should be offered adjuvant therapy, as they are the most
likely to derive a benefit, although there is currently some
debate regarding the exact definition of ‘high-risk’ stage II
CRC. Patients with stage IV disease require chemotherapy
or targeted therapies combined with surgery, where
appropriate. Whilst surgery, chemotherapy and radiation
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therapy are key contributors to CRC treatment, the re-
mainder of this article will focus on targeted therapies.
Targeted therapies in the treatment of CRC
As a consequence of improved understanding of the mo-
lecular pathology of cancer, a number of targeted agents
have been developed which have demonstrated improved
outcome in metastatic CRC (mCRC) patients, with com-
bination chemotherapy. Among the first of these drugs to
be developed and approved for use by the Food and Drug
Administration (FDA) in mCRC were the following:
1. Bevacizumab (Avastin™, Genentech/Roche, CA,
USA), a monoclonal antibody targeted to vascular
endothelial growth factor (VEGF) [22]; and
2. The anti-EGFR monoclonal antibodies cetuximab
(Erbitux™, Imclone Systems, NJ, USA [23]) and
panitumumab (Vectibix™, Amgen, CA, USA [24]).
Anti-angiogenic drugs (bevacizumab)
Folkman et al. [25] first suggested the concept of target-
ing angiogenesis in cancer over 40 years ago. In 2004,
the FDA approved bevacizumab as a first-line treatment
for patients with mCRC. This followed a phase III study
in 2004 on mCRC patients by Hurwitz et al. [22], which
demonstrated that the inclusion of this drug to 5-FU
combination therapy resulted in a ‘statistically significant
and clinically meaningful improvement in survival’ among
mCRC patients. Bevacizumab is a recombinant humanised
monoclonal antibody that specifically targets VEGF-A,
which is synthesised during tumour growth. Bevacizumab
is thus defined as an anti-angiogenic drug due to its ability
to prevent VEGF from interacting with appropriate recep-
tors in vascular endothelial cells. As a result, cell signalling
pathways that enhance angiogenesis, and thus the blood
supply for tumours, are diminished. Bevacizumab is com-
monly used in combination with standard chemothera-
peutic agents (e.g. 5-FU) as a first-line treatment for
patients with mCRC and improves the overall survival
(OS) of these patients by approximately 5 months [26,27].
In theory, by specific targeting of endothelial cells, anti-
angiogenic agents (such as bevacizumab) may avoid
potential tumour cell resistance, thus indicating their
usefulness in treating metastatic disease. Additionally,
in contrast to EGFR-based therapies, bevacizumab is
























Figure 1 Molecular classification of CRC as described by Jass [17]. Tumours are divided primarily on the basis of CIMP status and
microsatellite stability. Group 1 tumours show methylation of MLH1 and B-Raf mutations. They are characterised by CIMP+ and MSI-H, arise from
serrated polyps and account for approximately 12% of CRC. Group 2 tumours are similar, but show only partial methylation of MSH1 associated
with B-Raf mutation. They are CIMP+, MSS/microsatellite instable-low (MSI-L), arise from serrated polyps and account for approximately 8% of
CRC. Group 3 tumours show not only mutations in APC, Kras and/or p53 but also methylation of MGMT. These tumours are CIMP-L and MSS/MSI-
L, and show CIS. They can arise in either serrated or classical adenomas, and account for approximately 20% of CRC. Group 4 tumours are the
classical type described in Vogelstein's original model [20], which show mutations in APC, Kras and/or p53. These tumours demonstrate CIS and
are CIMP- and MSS. They arise in classical adenomas and make up approximately 57% of CRC. Group 5 tumours are those tumours arising in the
familial cancer syndrome, HNPCC. They show mutations in one of the DNA MMR genes, are CIMP-, but MSI-H and account for approximately 3%
of CRC (adapted from Ibrahim and Arends, [146]).
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effects are relatively rare [28]. This will be discussed in
more detail later.
Limitations and side effects of bevacizumab By tar-
geting angiogenesis, a generalised biological phenomenon
in the human body, bevacizumab-based therapies may re-
sult in toxicities affecting multiple organs. For example, in
the Hurwitz et al. trial, a significantly higher rate of ad-
verse effects was noted, including hypertension, anorexia
and proteinuria [22]. A recent retrospective analysis of
228 Japanese patients with mCRC [29] showed that 96
(42%) did not receive bevacizumab as part of their treat-
ment regime. In the majority of cases (76%), this was due
to bevacizumab-specific contraindications, whilst an Ital-
ian study [30] demonstrated that 10% of mCRC patients
had serious treatment-related toxicities. Of some concern
is the correlation between gastrointestinal perforation,
which occurs in 1%–2% of bevacizumab-treated patients,
and mortality rates. This was reviewed recently in a
community-based cohort of 1,953 CRC patients [31], and
the authors found that most toxic events were successfully
addressed by surgery. Other researchers have noted the
limited survival benefits observed in some bevacizumab
studies, whereby addition of bevacizumab to oxaliplatin-
based chemotherapy significantly improved progression-
free survival (PFS); however, OS differences did not reach
statistical significance nor was response rate improved [32],
whilst some preclinical and clinical studies have reported
that VEGF inhibition actually increased tumour invasive-
ness and metastasis, suggesting that bevacizumab may in-
directly stimulate new blood vessel growth (and tumour
dissemination) through a VEGF-independent mechanism
[33,34].
Although considered rare, some cutaneous side effects
of bevacizumab therapy have been observed, including
exfoliative dermatitis, peripheral sensory neuropathy,
skin discolouration and dryness [35]. However, it should
also be noted that two studies by researchers at Yale
University have suggested a potential association be-
tween skin rash occurrence in bevacizumab-treated
mCRC patients and a positive drug response [36,37],
whilst Manzoni et al. [38] have suggested a role for the
increased presence of circulating endothelial cells (CEC)
as future predictive biomarkers for bevacizumab-treated
mCRC patients.
Biomarkers and response to bevacizumab—potential
predictive markers? There is evidence that indicates
that biomarkers may be of value in determining response
to bevacizumab, as mentioned above. Such markers in-
clude vascular imaging, hypertension and polymorphisms
affecting components of the VEGF pathway. In addition,
profiles of circulating cytokines, growth factors and
angiogenesis-related molecules may also prove valuable as
prognostic and/or predictive markers.
Use of imaging tools Imaging approaches, such as dy-
namic contrast enhanced (DCE)-magnetic resonance
imaging (MRI) and 18F-fluorothymidine (FLT)-positron
emission tomography (PET), may be used to assess the
anti-angiogenic activity of bevacizumab. Small studies
undertaken in advanced biliary tract cancer [39,40] and
breast cancer [41] have indicated that such approaches
are promising as potential predictors of response. In the
malignant glioma study, FLT-PET at 1–2 and 6 weeks
was found to be a positive predictor of a survival benefit,
whilst in biliary tract cancers, changes in FLT-PET (after
2 cycles of bevacizumab) were found to be a significant
predictor of PFS and OS. In breast cancer patients re-
ceiving neoadjuvant chemotherapy plus bevacizumab,
DCE-MRI indicated that greater decreases in angiogenic
volume were associated with patients who derived a
clinical benefit [42]. Whilst data in the CRC setting is
more limited, there have been some indications that
DCE-MRI may predict tumour shrinkage in response to
combined bevacizumab and cytotoxic chemotherapy in
CRC liver metastases [43]. However, further assessments
using larger cohorts are necessary to determine if this
approach has future value as a predictive biomarker of
response to treatment.
Hypertension as a potential biomarker Recent studies
have indicated that the development of bevacizumab-
induced arterial hypertension may serve as a potential
predictive biomarker. Clinically, patients treated with
bevacizumab have shown a rapid rise in blood pressure,
and 5–18% have experienced grade 3 or 4 hypertension
[44]. Hypertension, therefore, may be a useful bio-
marker of VEGF activity and predict the anti-angiogenic
activity of bevacizumab. A number of small, single-arm
studies have evaluated this in pancreatic cancer [45],
renal carcinoma [46] and in CRC [47]. These studies
have indicated that bevacizumab-induced hypertension
(or the necessity for increased antihypertensive medica-
tion during bevacizumab treatment) was associated with
extended PFS or OS. Further analysis carried out retro-
spectively on phase III trials in metastatic breast cancer
and non-squamous, non-small cell lung cancer provides
support for the biomarker as a predictive marker of
clinical benefit [48,49]. In CRC, however, the situation
is less clear. Hurwitz et al. [50] undertook a retrospect-
ive analysis of two CRC studies and found that in only
one of these studies did hypertensive changes (during
bevacizumab therapy) predict a clinical benefit, as
measured by PFS and OS, whilst Dewdney et al. [51]
undertook a phase II study of bevacizumab-induced
hypertension of 45 patients with poor-risk colorectal
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liver-only metastases. Although 15% of patients developed
≥ grade 1 hypertension (whilst receiving neoadjuvantx
chemotherapy), and 4% developed grade 3 hypertension,
no correlation was found between this condition and
radiological response rate, PFS or OS.
This uncertainty could indicate that the predictive
value of bevacizumab-induced hypertension might not
extend to all cancers or treatment regimens, and thus,
further work on CRC in large scale, prospective studies
is required to elucidate the role of this as a potential
biomarker.
Circulating biomarkers Baseline measurements of cir-
culating VEGF levels have been shown to be prognostic
in a number of tumour types, including mCRC, lung
cancer and renal-cell cancer. These studies also indi-
cated that circulating VEGF levels were not predictive of
treatment response to bevacizumab-based treatment
regimes [52]. A recent study undertaken by Duda et al.
[53] looked at the concentrations of VEGF, placental
growth factor (PlGF), soluble VEGF receptor 1 (sVEGFR-1)
and sVEGFR-2. These were measured in plasma and urine
at baseline and during treatment in patients with locally
advanced rectal cancer. In this study, they found that
pre-treatment plasma sVEGFR-1, an endogenous blocker
of VEGF and PlGF, and a factor linked with ‘vascular
normalisation’ were associated with both primary tumour
regression and the development of adverse events after
neoadjuvant bevacizumab and chemoradiation [53].
A number of studies have been undertaken in an at-
tempt to identify other circulating prognostic or predict-
ive markers of bevacizumab therapy. A review of these
studies can be found in Jubb and Harris [54] and by
Wilson et al. [55]. In a study of 32 mCRC patients,
Abajo et al. [56] utilised ELISAs and multiplex bead
assays to determine if serum cytokines were predictive
of bevacizumab efficacy. This group noted that high
baseline serum levels of EGF and macrophage-derived
chemokine and low levels of interleukin-6 (IL-6), IL-8
and IL-10 were correlated with likelihood of improved
response. As mentioned previously, work by Manzoni
et al. [38] on a group of 24 mCRC patients (undergoing
bevacizumab treatment) indicated increased CECs and
the apoptotic fraction of CECs as future (mutually inde-
pendent) predictive biomarkers for this mCRC popula-
tion, and appear to confirm other similar studies on
CECs [57-61].
Polymorphisms in the VEGF pathway Interest in the
role of genetic variants in the VEGF pathway, as biomar-
kers for bevacizumab treatment outcome, has increased
in light of the finding that heritability accounts for al-
most 80% of the variance seen in VEGF levels [62]. In
metastatic breast cancer, Schneider et al. [48] identified
two VEGF genotypes (VEGF-2578AA and VEGF-1154AA)
which were significantly associated with improved OS in
the bevacizumab plus paclitaxel treatment group. However,
the same polymorphisms did not show any association
with a PFS benefit. Both of these polymorphisms have also
been associated with OS in a retrospective study of patients
with mCRC receiving either FOLFIRI (leucovorin, fluor-
ouracil, and irinotecan) plus bevacizumab, or XELIRI
(capecitabine and irinotecan) plus bevacizumab [63]. A
study undertaken by Lambrechts et al. [64] identified a
locus in VEGFR1, which correlates with increased VEGFR1
expression and poor outcome of bevacizumab-treated
patients with metastatic pancreatic adenocarcinoma and
metastatic renal-cell carcinoma, although no work has as
yet been undertaken in the CRC setting.
Despite the observations regarding the above poly-
morphisms, no data exist to indicate the biological sig-
nificance of these variants and their role in response to
treatment. As a result, additional work would provide a
better understanding of their relevance.
Anti-EGFR therapy
EGFR is a 170 kD glycoprotein located in chromosome
7 [65] and is a member of the transmembrane tyrosine
kinase receptor family, ErbB. EGFR is known to be over-
expressed in tumours of epithelial origin, including CRC.
EGFR activation is triggered by binding of peptide growth
factors (of the EGF family) to the extracellular domain of
the receptor and subsequently initiates both the RAS/RAF/
MAPK and the phosphatidylinositol 3-kinase (PI3K signal-
ling pathways. As a result, EGFR is directly involved in cell
proliferation and survival, and therefore contributes to
metastatic progression. Two classes of anti-EGFR therapies
exist. The first group is composed of monoclonal anti-
bodies to EGFR, whilst the second class includes tyrosine
kinase inhibitors (TKIs), such as erlotinib and gefitinib.
Tyrosine kinase inhibitors TKIs serve to block the cas-
cade of reactions crucial to tumour development and
survival; therefore, their anticancer properties have be-
come an important focus for drug development by the
pharmaceutical industry. To date, TKIs have obtained
FDA approval for use in a range of cancers, including
chronic myeloid leukaemia, acute lymphocytic leukae-
mia, non-small cell lung cancer and pancreatic cancer.
Moreover, the use of the TKIs sunitinib, sorafenib and
pazopanib into clinical care has doubled the PFS of
patients with renal-cell cancer [66,67]. As a result, sora-
fenib (originally developed as a BRAF inhibitor) is cur-
rently being tested in phase II trials for mCRC. Whilst
current phase III trials of novel targeted agents for
mCRC (specifically the small molecule TKIs, erlotinib
and gefitinib) have been approved for targeting several
cancers, neither has yet been approved for treating CRC.
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Additionally, the TKI imatinib has been used to treat
advanced gastrointestinal stromal tumours; however,
these tumours represent a very small proportion
(<3%) of GI malignancies, are thus classed in a differ-
ent category to CRC and are termed as connective
tissue tumours.
Recent work has indicated the ability of TKIs to
strongly suppress PI3K signalling (and possibly other
pro-survival pathways) in CRC, suggesting that these
treatments may have great therapeutic value [68].
Despite this, however, there has been no FDA ap-
proval granted to TKIs as new targeted agents for the
treatment of mCRC since 2004. As a consequence, we
will confine our discussions of anti-EGFR therapies to
monoclonal antibodies.
Monoclonal antibodies to EGFR Two EGFR antago-
nists, cetuximab (Erbitux™, Imclone Systems) and pani-
tumumab (Vectibix™, Amgen) were FDA-approved for
the treatment of mCRC in 2004 and 2006, respectively.
Cetuximab is a chimeric immunoglobulin IgG1 mono-
clonal antibody that targets the ligand-binding domain
of EGFR, whilst panitumumab is a human IgG2 mono-
clonal antibody. Both antibodies prevent EGFR autop-
hosphorylation by binding to the extracellular domain
and thus inhibiting activation of the downstream cell
signalling pathways, MAPK and PI3K. Each antibody
has been approved for the treatment of advanced CRC
based on various parameters, including QoL, PFS and
OS when used individually or in combination with
standard chemotherapeutics.
Cetuximab An early phase II trial that assessed the
efficacy of cetuximab [69] by treatment-refractory CRC
patients demonstrated the drug to have ‘modest activity’
that was well tolerated by patients. This study also noted
that presence and severity of drug-induced acneiform
skin rash correlated positively with survival [69]. Whilst
in a seminal study of 329 mCRC patients, Cunningham
et al. [70] showed that cetuximab had ‘clinically signifi-
cant activity’ in patients with irinotecan-refractory CRC
when given alone or in combination with this drug.
Combination therapy patients demonstrated a higher re-
sponse rate, longer median progression times and longer
median survival times. Similarly, in a phase II trial of
cetuximab by Vincenzi et al. [71], this anti-EGFR therapy
was found to be clinically active in mCRC patients who
were refractory to other regimens (irinotecan and oxali-
platin). In 2006, a multicentre study by Lenz et al. [72]
demonstrated that cetuximab was well tolerated by
mCRC patients who were previously unresponsive to iri-
notecan, oxaliplatin and fluoropyrimidines. As in previ-
ous studies, skin rash severity was correlated with drug
response. Jonker et al. [73] undertook a study of
cetuximab in treatment-resistant mCRC patients and
noted that this drug therapy improved OS, PFS and pre-
served QoL measures, whilst a rash of grade 2 or above
was robustly associated with improved survival.
Panitumumab Following on from the successful use of
cetuximab, a second anti-EGFR antibody, panitumumab,
was introduced. Similar to cetuximab, panitumumab
demonstrated significant anti-tumour activity in treat-
ment-refractory mCRC patients, as well as a good safety
profile. Studies of panitumumab by Gibson et al. [74] in
a randomised phase III trial also demonstrated a reduc-
tion in tumour progression (46%) of patients with
mCRC. Improved OS was positively correlated with se-
verity of an acneiform skin rash, which was observed in
90% of subjects undergoing this treatment regime. Fur-
ther, in a randomised phase III trial comparing panitu-
mumab with other treatment regimens, including
bevacizumab, Wainberg and Hecht [75] concluded that
this therapy had ‘significant activity’ when used alone
and improved PFS when compared with best supportive
care (BSC). This finding was also observed in a study on
treatment-refractory mCRC patients by Van Cutsem
et al. [76]. Moreover, response rates of 10% were
observed in panitumumab-treated subjects versus none
for BSC. Yet, it should be noted that in this study, there
was no change in OS. In a randomised phase III trial,
Siena et al. [77] showed improved PFS in panitumumab-
treated mCRC patients who were previously unrespon-
sive to other regimens. Therefore, as a consequence of
its success in addressing mCRC, panitumumab was
approved by the FDA for use in the treatment of CRC
and lung cancer.
Limitations and side effects of EGFR therapies Skin
toxicities are a common adverse event associated with
EGFR inhibitors, with up to 80% of patients presenting
with a skin rash (acneiform) on the scalp, face, neck and
upper trunk [78]. This rash tends to occur within 3
weeks after therapy initiation, and it has been demon-
strated that this response is reversible upon therapy
cessation. In general, however, most studies suggest that
EGFR therapies are well tolerated by patients. Both
cetuximab and panitumumab have shown acceptable
safety profiles in patients with mCRC. For example,
Mitchell et al. [79] recently demonstrated that panitu-
mumab (combined with irinotecan) had an acceptable
toxicity profile in mCRC patients. Although in some
cases, hypersensitivity reactions have been observed
with cetuximab treatment [80,81]. By contrast, hyper-
sensitivity reactions are rare with panitumumab which
has been indicated as an alternative treatment for
patients at risk from cetuximab-induced anaphylaxis.
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Biomarkers and response to anti-EGFR therapy—
potential predictive markers?
Skin toxicity as a biomarker of response to anti-
EGFR therapy
Research has suggested that adverse skin events
following anti-EGFR therapies may be indicative of
patient response. For example, cetuximab-induced
skin rash in mCRC patients has been strongly
correlated with improved PFS, OS and response
rates in a number of studies [69,82,83]. Additionally,
panitumumab has demonstrated a strong association
between skin toxicities and improved outcome
[84,85]. Further pre-emptive [86] and prospective
toxicity studies will enable researchers to clarify the
mechanisms underlying the skin rash response in
these therapies.
Major progress has been made using anti-EGFR therapies,
including the understanding of biomarkers and their
contribution to drug response. Despite the success of anti-
EGFR therapy, however, not all patients obtain the same
benefits. This has led to the search for biomarkers which
might indicate the patient population that would benefit
most from anti-EGFR therapy. As such therapies are
expensive and potentially toxic, the search for such
biomarkers is driven, not only from the clinical and
scientific community, but also from the payor community.
Therefore, specific targeting of patients who would benefit
from this treatment is being actively pursued.
EGFR polymorphisms/mutations and overexpression
To date, a small number of pharmacogenetic studies
have identified EGFR polymorphisms as potential
biomarkers in predicting response to anti-EGFR
therapies in mCRC and non-small cell lung cancer
[87-89]. By contrast to lung adenocarcinoma, however,
EGFR mutations in CRC are somewhat rare [90-92],
thus limiting their utility as biomarkers at present.
Immunohistochemical (IHC) studies of CRC
tumours indicated that patients with EGFR-positive
tumours benefit from anti-EGFR therapy [93]. Since
2004, the combination of a diagnostic test for EGFR
(EGFR PharmDx™ Kit, Dako, Cambridgeshire, UK),
and the subsequent application of cetuximab or
panitumumab in EGFR-positive colon carcinomas
has been approved by FDA, reviewed in [94].
However, subsequent studies have shown that
EGFR-negative tumours may also benefit from
cetuximab therapy [69,95,96]. These studies appear
to indicate that analysis of EGFR expression via
IHC may not be as reliable in predicting the
efficacy of EGFR therapy. As a consequence of
these disappointing results, researchers have instead
undertaken a search for alternative biomarkers.
These investigations have lead to a focus on
downstream effectors of EGFR signalling, including
RAS family members, BRAF and the PI3K pathway,
amongst others. Each of these potential biomarkers
will be discussed individually.
1. KRAS
KRAS is a member of the RAS proto-oncogene
family which is transiently activated by the action of
ligand binding of EGFR. The RAS family also
includes NRAS and HRAS. KRAS mutations have
been reported in approximately 40% of human CRC
[97-100]. The majority (85%) of these mutations
occur in codons 12 and 13, with a smaller number
occurring in codons 61, 117 and 146 [101-103].
Oncogenic mutation in KRAS renders the protein
constitutively active, thus maintaining it in the GTP-
bound conformation.
Due to the common occurrence of KRAS mutations
in CRC, a number of studies have examined their
potential clinical relevance. Some studies have shown
that the presence of a KRAS mutation may have
prognostic significance, as reviewed in [92]. This
effect appears to be borderline and confined to
certain mutations (particularly the G12V mutation).
Moreover, the effect may be confined to certain
stages of CRC.
The importance of KRAS mutation was truly realised
with the advent of anti-EGFR monoclonal antibodies
as a treatment for mCRC. These were introduced
into clinical use around 2004 and showed reasonable
response rates of 10%–15% in mCRC. However, their
role was revolutionised by the discovery that patients
whose tumours harbour mutant forms of KRAS do
not respond to anti-EGFR therapy [104]. Although
the results of this study were statistically significant,
patient numbers were small and there was a need for
greater sample sizes. Subsequent studies with larger
numbers confirmed these findings [85,105]. Meta-
analyses of the available randomised controlled trials
have gone on to further support these results,
demonstrating that a benefit from anti-EGFR therapy
is only seen in patients whose tumour is wild-type
for KRAS [106-108]. In these studies, no difference
was found in the predictive effects of mutations in
different codons.
Based on these and other studies, the American
Society of Clinical Oncology recommended that
patients who are candidates for anti-EGFR therapy
should have their tumour tested for KRAS mutation.
If a codon 12 or 13 mutation is detected, these
patients should not be treated with anti-EGFR
therapy [109]. Similarly, the Canadian Expert Group
has stated that KRAS status should be determined
whenever anti-EGFR therapy is being considered in
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the setting of mCRC [110,111]. In 2009, the FDA
updated the product labels for cetuximab and
panitumumab, indicating that patients with CRC
tumours harbouring KRAS mutations were unlikely
to derive benefit from these therapies. However,
these guidelines may have to be re-visited, as it has
been shown (in one study) that patients with a G13D
mutation showed improved survival compared to
patients with other mutations, indicating that this
patient group may respond to therapy [112]. This is,
therefore, an area that will require further study.
2. KRAS mutation heterogeneity
Although there is now widespread agreement that
the presence of a KRAS mutation indicates that a
patient is unlikely to respond to anti-EGFR therapy,
there is some concern around the area of tumour
heterogeneity. Some studies have shown a strong
correlation in mutation status between primary
tumours and distant metastases [113,114]. Yet, other
studies have suggested that there is significant
heterogeneity in the expression of KRAS mutations
within a tumour [115-118] and also between primary
tumour samples and lymph node metastases
[113,117]. This could theoretically lead to false
negative results, i.e. there is a KRAS mutation
present within a tumour, but the portion sampled for
testing does not contain the mutation (or there are
insufficient numbers of tumour cells with the
mutation) to enable detection. Whilst this issue has
been raised in the literature, to date, no reliable data
have been provided to suggest that appropriate
sampling protocols are in place. A robust sampling
method would address this concern [118].
3. Approach used for KRAS mutation testing
The analysis of tumour samples for KRAS mutations
is undertaken using samples of fresh-frozen or
paraffin-embedded tumour material. A pathology
review of the material is essential to establish that
the sample contains sufficient tumour cells for
analysis. If necessary, enrichment for tumour
material may be carried out using tumour
microdissection. DNA is then extracted from the
sample and used for molecular testing using
sequencing or pyrosequencing-based approaches, or
an allele-specific PCR-based approach. Currently,
there are no FDA-approved protocols for KRAS
testing. However, a number of laboratory-based
assays can be utilised, provided they are run under
CAP certification or other CMS-approved
certification (as required by the CLIA regulations of
1988). In countries where CE marking is accepted,
there are a number of approved KRAS mutation tests
available for use in CRC. A summary of these tests is
listed in Table 1 below.
4. The cost/benefit ratio of KRAS testing
The use of mutation testing has obvious benefits to
patients by preventing exposure of those patients
unlikely to respond, to potential toxic effects of a
given drug regime. Moreover, there are significant
economic benefits. Studies have demonstrated that
the investment in testing for KRAS and BRAF
(discussed later) results in significant cost savings
[119,120]. For example, as early as 2009, researchers
were estimating that routine testing for KRAS
mutations in CRC patients would save approximately
$740 million a year, whilst more recently,
Vijayaraghavan et al. [121] have estimated that KRAS
mutation testing saves $7,500–$12,400 per patient in
the USA and €3,900–€9,600 per patient in Germany.
Other potential biomarkers of mCRC The finding of a
link between KRAS mutation status and anti-EGFR ther-
apy has led to the investigation of other downstream
effectors as potential biomarkers. The most investigated
candidates have been NRAS, BRAF, PI3K and phosphat-
ase and tensin homologue (PTEN). Each of these will be
dealt with in more detail in the next section.
1.NRAS
Mutations in NRAS are less common than KRAS and
are present in approximately 2.6% of CRC cases
[112]. As a result of this infrequency, only a limited
number of studies investigating the predictive
potential of NRAS have been undertaken. De Rooke
et al. [112] showed a significant difference in
response rate between patients in whom tumours
showed an NRAS mutation (1/13, 7.7%) versus
patients whose tumour was wild-type NRAS (110/
289, 38.1%). Although, it should be noted that no
significant difference in disease control rate, PFS or
OS was observed.
2. BRAF
V-raf murine sarcoma viral oncogene homologue B1
(BRAF) is a serine-threonine kinase, which is
downstream of RAS. BRAF is an important oncogene
and is found to be mutated in a number of
malignancies, including sporadic CRC, where the rate
of mutation is of the order of 15% [108]. BRAF
mutation has been associated with the serrated
pathway of tumour development, and these tumours
tend to be in groups 1 and 2 of the Jass classification
[17]. The vast majority of BRAF mutations in CRC
are the V600E mutation, which leads to constitutive
activation of the kinase [122].
A number of the earlier studies examining
biomarkers associated with a response to anti-EGFR
therapy did not contain any CRC patients with a
BRAF mutation. This has generally been a problem,
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where low patient numbers have led to poor
statistical power. However, more recent research has
overcome this, and studies have generally shown that
the presence of a BRAF mutation correlates
negatively with response to anti-EGFR therapy
[98,112,123,124]. In a cohort of 173 CRC patients,
Laurent-Puig et al. [123] noted that five patients with
a BRAF mutation showed a significant decrease in
PFS and OS when compared to BRAF wild-type
patients treated with cetuximab. Although the
numbers were small, this study did demonstrate
statistical significance. De Roock et al. [112] have
reported the largest cohort of BRAF mutant tumours
to date with 36/761 (4.7%) of tumours tested
containing a BRAF mutation. This group also
demonstrated a significant difference in response rate
between BRAF mutant and wild-type tumours.
Lin et al. [106] recently performed a systematic
review of the predictive value of BRAF in mCRC.
They concluded that, although the quality of the
studies is impaired by their retrospective nature,
there is definite evidence supporting the view that
mutation of BRAF predicts a lack of response to anti-
EGFR therapy. A subsequent meta-analysis by Mao
et al. [125] has supported the results of these
individual studies. This study observed that in KRAS
wild-type patients, the objective response to anti-
EGFR therapy was 0% in BRAF mutant tumours
versus 36.3% in BRAF wild-type tumours. Further,
Prahallad et al. [126] have recently suggested that
BRAF (V600E) mutant colon cancers may benefit
from a combined therapy of BRAF and EGFR
inhibitors.
The data has now developed to the point where
testing for BRAF is becoming part of the clinical
routine for the management of mCRC patients in
some centres. BRAF mutation testing is being
incorporated into commercially available test kits for
this purpose. It has also been shown that KRAS and




catalytic subunit alpha, PIK3CA, is a phospholipid
kinase, which is downstream of EGFR but signals via
AKT rather than via the canonical MAP kinase
pathway. As with KRAS and BRAF, PIK3CA
undergoes activating mutations. The most common
of these occurs in either exon 9 (approximately 60%,
G1624A; E542K) or exon 20 (approximately 25%,
A3140G; H1047R). These mutations result in
different effects. Both are activating mutations, but
exon 9 mutations require an interaction with
activated RAS for subsequent downstream signalling.
In the case of the exon 20 mutation, downstream
signalling is independent of RAS [127].
There have been some suggestions that, in an in vitro
setting at least, this may be the more important
pathway in terms of the oncogenic effect of EGFR
signalling [128]. Therefore, there has been significant
interest in whether components of this pathway will
impact on response to anti-EGFR therapy. As with
BRAF studies, small cohort sizes have hampered
attempts to definitively determine the predictive
value of PIK3CA mutations.
There has been some conflicting clinical data
regarding the importance of PI3K mutations in
predicting response to anti-EGFR therapy. In their
initial study, Lièvre et al. [104] did not show any
correlation between PIK3CA mutation and response
to cetuximab, but their study only included three
patients with a PIK3CA mutation. A larger study
(containing 15 tumours with a PIK3CA mutation) by
Sartore-Bianchi et al. [129] showed a significant
association between mutation of the gene and
resistance to cetuximab or panitumumab. Similar
Table 1 A number of approved KRAS mutation tests available for use in CRC
Test name Manufacturer Test details
Cobas KRAS Mutation Test Roche Diagnostics The test detects mutations in codons 12, 13 and 61 of
the KRAS gene
AmoyDx KRAS test Amoy Detects the seven most common activating mutations of
the KRAS gene in cancer tissue
SURVEYOR Scan K-RAS Mutation Detection Kit Transgenomic Inc Detects mutations in exon 2 of the K-RAS gene (codon
12 and 13)
PyroMark Q24 KRAS Assay-Kit Qiagen Able to detect all major and minor known mutations in
the KRAS codons 12, 13 and 61, and, in addition, allows
the discovery of new mutations as well
TheraScreen: K-RAS Mutation Kit Qiagen K-RAS Kit will detect seven K-RAS mutations in codons
12 and 13 of the K-RAS oncogene
Hagan et al. The EPMA Journal 2013, 4:3 Page 9 of 16
http://www.epmajournal.com/content/4/1/3
results were obtained by Souglakos et al. [98].
However, these results were not replicated by others
[130]. These differing results may have been
reconciled by the work of De Roock et al. [112].
They [112] showed that exon 9 mutations had no
effect on response to treatment, whilst exon 20
mutations were significantly correlated with objective
response, PFS and OS. In their study, no patient with
an exon 20 mutation responded to cetuximab-based
therapy. A recent meta-analysis has supported these
results, showing an objective response rate of 0% in
patients whose tumours harboured a PIK3CA exon
20 mutation [125]. By contrast, the objective
response rate was found to be 37% in patients with
tumours that were wild-type for PIK3CA exon 20.
4. PTEN
PTEN is a key inhibitor of the PIK signalling
pathway, and its expression has been shown to be
lost in a number of different human tumours,
including CRC. The mechanism of decreased
expression can be driven by mutation or epigenetic
phenomena, with up 13% of CRC in the COSMIC
database showing a PTEN mutation. It has been
suggested that this latter mechanism is particularly
prevalent in tumours with high levels of MSI [131].
A number of CRC studies have examined PTEN
expression and response to anti-EGFR therapy. These
studies have primarily used IHC to assess expression
at the protein level, and some have shown a
correlation between PTEN expression and clinical
response [123,132-134]. However, other studies have
not shown such a relationship [135-137]. For
example, Loupakis et al. [138] showed that PTEN
expression in metastatic, but not in primary, tumours
correlated with response to cetuximab. Moreover,
Negri et al. [139] used indirect immunofluorescence
to determine PTEN loss and showed that none of the
patients with PTEN loss responded to cetuximab
therapy. This was compared to a 30% disease
progression rate in patients whose tumour retained
PTEN expression [124]. These differing results may
be due to the method of determining PTEN loss, i.e.
IHC. Moreover, the studies examining PTEN have
used differing protocols, antibodies and scoring
systems, and this is reflected in the differing number
of tumours found to be PTEN-deficient. This
conflicting evidence has led the authors of at least
one systematic review to conclude that, at present,
PTEN expression levels cannot robustly predict
response to anti-EGFR therapy [106]. Therefore,
until there is further study in this area and until a
standardised approach to assessment can be
implemented, it appears that PTEN cannot be used
in routine clinical practice.
5. pAKT
Closely associated with PIK3CA and PTEN testing, is
activated AKT (pAKT). The presence of pAKT
indicates activation of the pathway and therefore
may indicate PIK3CA mutations, PTEN loss or
activation of the pathway via a different mechanism.
A number of studies have assessed the effect of
pAKT expression in CRC and attempted to correlate
it with response to anti-EGFR therapy. To date,
however, no significant correlation has been found
[138,140,141].
Drug/diagnostic co-development—future approaches for
personalised medicine
With the advance of our knowledge around patient seg-
mentation, it will be necessary to consider the develop-
ment of a companion diagnostic to aid treatment
decision making during the drug development process.
Ideally, the development of the diagnostic and the drug
should happen in parallel, and the regulatory approval of
both should be achieved simultaneously. Recent US FDA
draft guidance on the development of companion diag-
nostics has been published [142]. In this draft guidance,
the FDA sets forth its expectations for the development
of companion diagnostic tools that will be used to deter-
mine treatment choices. This document also outlines the
requirement for drug development and diagnostic tools
to be carried out simultaneously. However, as recent
events have indicated, this situation is not always achiev-
able. In many circumstances, the understanding of the
biology of the action of the drug in the intended disease
population is evolving. Therefore, the knowledge of
which biomarkers are important for the selection of ap-
propriate patients for treatment may not be clear early
enough in the programme to make the development of a
diagnostic (in time for launch) a realistic goal. This is
illustrated with the understanding around the role of
KRAS mutations in resistance to anti-EGFR monoclonal
antibody treatment. It is evident from recent clinical
data from the phases II and III trials for panitumumab
and cetuximab, where patients whose tumours harbour
mutations in KRAS are less likely to respond to treat-
ment. Retrospective analyses across seven randomised
clinical trials suggest that anti-EGFR-directed monoclo-
nal antibodies are not effective for the treatment of
patients with mCRC containing KRAS mutations. This
finding has led to the inclusion of information on the
FDA-approved drug label for panitumumab and cetuxi-
mab (Indications and Usage section) to the effect that
treatment of patients whose tumours harbour KRAS
mutations is not recommended. Currently, however,
there is no FDA-approved companion KRAS mutation
test for either drug. The key rationale for KRAS muta-
tion testing in this patient population is to avoid the
Hagan et al. The EPMA Journal 2013, 4:3 Page 10 of 16
http://www.epmajournal.com/content/4/1/3
exposure of patients to unnecessary drug toxicities in
situations where there is unlikely to be any clinical bene-
fit. In addition, this avoids unnecessary financial burdens
on the healthcare system. However, it does remain that
CRC patients whose tumours harbour KRAS mutations
have a high unmet medical need. Understanding the role
of additional biomarkers in CRC and their potential use
as predictive markers of drug response will show pos-
sible utility for the future and will allow us to see an in-
crease in the development of companion diagnostic
tools to support this.
Recent National Institute for Health and Clinical
Excellence ruling on use of bevacizumab
The UK National Institute for Health and Clinical Excel-
lence has recently published guidelines on the use of
VEGF- and EGFR-targeted therapies in treating mCRC
patients who have failed to respond adequately to first-
line treatments [143]. The guidelines have acknowledged
the fact that cetuximab showed benefits in terms of PFS
and OS when used in KRAS wild-type mCRC patients
compared with BSC alone. They also noted that panitu-
mumab, given as a monotherapy, had shown a benefit in
terms of PFS. However, following cost-benefit analysis,
the committee concluded that cetuximab and panitumu-
mab (in addition to bevacizumab) were ‘not a cost-effective
use of National Health Service (NHS) resources’ [143].
This analysis highlights the need to continue to refine our
strategies in terms of the use of biomarkers and to identify
those patients who are likely to derive the most benefit
from these treatments. This will not only promote genuine
personalised medicine, but will also enable us to use these
therapies in a manner that will not put undue strain on fi-
nite healthcare resources.
Conclusions
In recent years, significant steps have been made in the
diagnosis and successful treatment of CRC. Researchers
and clinicians, however, are still faced with challenges,
not least the detection and management of tumours
with varied gene mutation status. Further clarification
of the molecular pathology of CRC may improve treat-
ment options as well as improve QoL and ultimately,
the long-term survival of patients with this condition.
As new technologies emerge allowing the identification
of CRC gene mutation status, this information will in-
form clinicians as to the most appropriate and effica-
cious form of treatment. This individualised approach
to managing mCRC fits in well with the PPPM model
put forward by EPMA [144,145]. However, in order to
gain most benefit from these novel technologies, tar-
geted therapy must be informed by well-designed stud-
ies, large cohort sizes and internationally standardised
detection protocols. Therefore, it is imperative that
scientists and clinicians collaborate closely in develop-
ing new ways to deal with the vast quantities of data
generated by mutational analyses in order to make sense
of the underlying mechanisms of CRC. As human popu-
lations are living longer, healthcare systems around the
world will be challenged to find new ways of dealing
with CRC to improve global health.
Expert recommendations
The following are expert recommendations:
 Routine KRAS and BRAF mutation testing of
patients with mCRC who are being considered for
anti-EGFR therapy to ensure they receive the most
appropriate therapy whilst being spared exposure to
non-beneficial therapeutic effects.
 PIK3CA and PTEN have also shown promise as
informative biomarkers for EGFR therapy, but
further studies are necessary before they can be used
clinically on a routine basis.
 Panel-based biomarker testing platforms should be
developed as a way to ensure that maximal value
can be derived from limited clinical material.
 VEGF inhibitors have shown promise in the
treatment of mCRC, but more research is required
into identifying predictive markers for patient
response. This will allow a more personalised
approach to anti-VEGF treatments in the future.
 Access to high-quality tumour material for
biomarker testing is of paramount importance;
therefore, tissue collection and storage procedures
must be standardised internationally.
 Development of internationally accessible bio-banks
for CRC tissues is necessary to progress high-quality
biomarker research.
 Good practice is essential in maintaining detailed
patient records for developing PPPM, based on
multifactorial data, e.g. sex, age, weight, ethnicity,
lifestyle, and prior therapy regimens.
 High stringency of genomic and proteomic assays is
required across research labs to ensure
reproducibility of data.
 Early biomarker discovery, coupled with approaches
to ensure appropriate co-development of formative
companion diagnostics, should be a standard
practice in all drug development programmes.
 Improved clinical trial design with more stringent
stratification of patient cohorts.
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